Horizon Therapeutics plc: Topline Data for Dazodalibep (HZN-

Detailed results to be presented at upcoming medical congress Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2, randomized, double-blinded, placebo-controlled trial of dazodalibep

Related Keywords

United States , Ireland , Putte , Mecklenburg Vorpommern , Germany , Theresa Podrebarac , Tina Ventura , Geoff Curtis , Ray Gordon , Exchange Commission , Instagram , Linkedin , Twitter , Facebook , Nasdaq , Corporate Affairs , United States Securities , Vice President , Chief Investor Relations Officer , Corporate Affairs Chief Communications Officer , Horizon , Herapeutics , Topline , Data , Azodalibep , 920 , Meets , Primary , Ndpoint , Rheumatoid , Arthritis ,